Shanghai Junshi Bio announces the official launch of its human experiment sinoping anti-theme JS016

Shanghai Junshi Bio announced that it has launched a clinical study on its anti-neo-coronavirusCOVID-19antibody (JS016) in China, and has completed the first case of subject administration at Huashan Hospital, affiliated with Fudan UniversityJS016 was developed in collaboration with Lilly and is expected to begin clinical trials in the United States in the second quarter of this yearFeng Hui, chief operating officer ofJunshi, said that JS016 is separated from the blood of patients recovering from theof the new crown virusinfection, hoping to protect healthy people with a high risk ofinfection, such as medical staff and the elderlyantibody drugs will be more expensive than vaccines because they contain large quantities of expensive protein searlyes in a single dose"Vaccines are cheap and suitable forimmunizationnationwide, but older people with weakmay not respond as much to the vaccine as healthy adults andchildren , and antibodies can better protect them from the virus," said Feng, of the While more research is needed to determine the amount of protein in a single dose, Feng said the production capacity and supply channels of Jundi biocane could produce enough doses by the end of the year to provide "absolutely no problem" for 100,000 people